8 active not recruiting, 8 completed, 6 terminated, 4 recruiting. 12 Phase 2, 8 Phase 3, 4 Not applicable, 4 Phase 1.
Follow Alliance Foundation Trials, LLC.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer Durvalumab 50 MG/ML - Small Cell Lung Cancer (SCLC) | Phase 2 | Recruiting | Alliance Foundation Trials, LLC. | 65 | 2026-02-12 | 2026-10-15 |
| Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer Financial Hardship Screening, Enhanced Usual Care - Advanced Cancer, Metastatic Cancer | Not applicable | Recruiting | Alliance Foundation Trials, LLC. | 1000 | 2025-07-01 | 2026-05-12 |
| Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC Atezolizumab, Tiragolumab - NSCLC | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 178 | 2023-12-07 | 2026-10-01 |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine - Triple Negative Breast Cancer | Phase 3 | Recruiting | Gilead Sciences | 1514 | 2022-12-12 | 2026-10-13 |
| Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM Daratumumab, Pomalidomide - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Alliance Foundation Trials, LLC. | 2022-10-01 | 2023-01-27 | |
| Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab - Metastatic Breast Cancer | Phase 3 | Terminated | SOLTI Breast Cancer Research Group | 61 | 2022-03-28 | 2026-06-25 |
| Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity Amcenestrant, Tamoxifen, Amcenestrant-matching placebo - Breast Cancer | Phase 3 | Terminated | Sanofi | 3 | 2022-02-17 | 2025-09-16 |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib - Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Alliance Foundation Trials, LLC. | 148 | 2021-10-20 | 2026-04-01 |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Darolutamide, Enzalutamide - Metastatic Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Completed | Alliance Foundation Trials, LLC. | 111 | 2021-08-17 | 2026-09-21 |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 1140 | 2021-06-09 | 2026-06-08 |
| CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer Durvalumab, Surgery, Radiotherapy - Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 38 | 2021-03-10 | 2026-09-23 |
| Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM Lenalidomide, Ixazomib, Daratumumab Injection - Myeloma, Multiple | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 79 | 2020-10-21 | 2025-12-18 |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Ibrutinib, Lenalidomide, Dexamethasone - Refractory Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Completed | Alliance Foundation Trials, LLC. | 14 | 2019-08-29 | 2026-01-06 |
| Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Nivolumab - Autoimmune Diseases, Non-small Cell Lung Cancer | Phase 1 | Terminated | Alliance Foundation Trials, LLC. | 7 | 2019-06-27 | 2023-02-15 |
| Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Palbociclib, Ibrutinib - Mantle Cell Lymphoma, B Cell Lymphoma | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 39 | 2018-09-11 | 2026-10-02 |
| A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin - Triple Negative Breast Cancer | Phase 3 | Terminated | Hoffmann-La Roche | 2199 | 2018-08-02 | 2024-08-21 |
| Atezolizumab Immunotherapy in Patients With Advanced NSCLC Atezolizumab - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Alliance Foundation Trials, LLC. | 64 | 2017-11-01 | 2023-05-24 |
| Electronic Patient Reporting of Symptoms During Cancer Treatment Patient Self-Reporting of Symptoms, Usual Care Delivery - Metastatic Cancer | Not applicable | Completed | Alliance Foundation Trials, LLC. | 1197 | 2017-10-30 | 2025-01-14 |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer palbociclib, trastuzumab, pertuzumab - HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer | Phase 3 | Active not recruiting | Alliance Foundation Trials, LLC. | 518 | 2017-06-21 | 2026-10-22 |
| Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Topotecan, Pembrolizumab - Small Cell Lung Cancer | Phase 2 | Terminated | Alliance Foundation Trials, LLC. | 9 | 2017-05-20 | 2023-02-15 |
Showing 20 of 27. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms (4) · Prostatic Neoplasms (4) · Multiple Myeloma (3) · Neoplasm Metastasis (2) · Small Cell Lung Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Carcinoma, Ductal (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Endometrial Neoplasms (1) · Financial Stress (1)
atezolizumab (4) · palbociclib (4) · Dexamethasone (3) · Letrozole (3) · pembrolizumab (3) · Calcium Dobesilate (2) · Fulvestrant (2) · Lenalidomide (2) · Nivolumab (2) · Paclitaxel (2) · Surgical Procedures, Operative (2) · Tiragolumab (2) · daratumumab (2) · durvalumab (2) · ibrutinib (2)
United States (24) · Spain (6) · Germany (5) · Australia (4) · Belgium (4) · France (4) · Italy (4) · Japan (4) · South Korea (4) · United Kingdom (4) · Austria (3) · China (3) · Ireland (3) · Poland (3) · Portugal (3)
Evanthia Galanis, MD (8) · Monica Bertagnolli, MD (4) · Helen Ross, MD (2) · Alastair Thompson, MD (1) · Aleix Prat, MD (1) · Andrew Yee, MD (1) · Angela DeMichele, MD (1) · Ann Partridge, MD, MPH (1) · Chi-Fu Jeffrey Yang, MD (1) · Dan G Stover, MD (1) · David Cameron, Professor of Oncology (1) · David Kozono, MD (1) · Deborah Schrag, MD MPH (1) · Erica Mayer, MD (1)
PMID 12954578, PMID 25524798, PMID 30032196, PMID 30862637, PMID 32450725, PMID 33112661, PMID 33369581, PMID 33460574, PMID 34172290, PMID 34874182, PMID 34995105, PMID 35661856, PMID 37207300, PMID 37266947, PMID 37556775, PMID 38261983, PMID 38421252, PMID 38922307, PMID 39052256, PMID 39289750, PMID 39503942, PMID 39665585, PMID 39665588, PMID 39849600, PMID 39883436, PMID 39920394, PMID 40140172, PMID 40215451, PMID 40408610, PMID 40896848, PMID 41604639, PMID 42561994
2014 (1), 2016 (1), 2023 (1)